Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Philogen SpA ( (IT:PHIL) ) has issued an update.
Philogen S.p.A. announced an update on its share buyback program, revealing the purchase of 50 shares between September 29 and October 3, 2025, at an average price of Euro 22.90 per share, totaling Euro 1,145.00. Since the program’s inception, the company has acquired 31,045 shares, representing 0.0764% of its share capital, amounting to Euro 693,338.82. This strategic move is part of Philogen’s broader efforts to manage its capital structure, potentially enhancing shareholder value and reinforcing its market position in the biotechnology sector.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR25.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company specializing in the research and development of pharmaceutical products aimed at treating high-mortality diseases. The company focuses on discovering and developing targeted anti-cancer drugs using high-affinity ligands for tumor markers. Philogen’s main therapeutic strategy involves tumor targeting, which selectively delivers potent therapeutic agents to tumor masses while sparing healthy tissues. The company has developed ligands based on monoclonal antibodies specific to antigens in tumor-associated blood vessels. Philogen aims to generate, develop, and commercialize innovative products for diseases lacking satisfactory therapies, leveraging proprietary technologies and a broad portfolio of patents.
YTD Price Performance: 21.54%
Average Trading Volume: 15,772
Technical Sentiment Signal: Buy
Current Market Cap: €693.1M
Learn more about PHIL stock on TipRanks’ Stock Analysis page.